Cetn3 Antibody

What is Centrin 3 and what are its key biological functions?

Centrin 3 (CETN3) is a small calcium-binding protein encoded by the CETN3 gene. In humans, the canonical protein consists of 167 amino acid residues with a molecular mass of approximately 19.6 kDa . As a member of the Centrin protein family, CETN3 plays fundamental roles in microtubule-organizing center structure and function. It is primarily localized in the nucleus and cytoplasm, with particular concentration at the centrosome .

CETN3 serves two major cellular functions. First, it acts as a structural component in centrosomes and centrioles. Second, it functions as a component of the TREX-2 complex, which is involved in the export of mRNAs to the cytoplasm through nuclear pores . Interestingly, recent research has revealed that CETN3 is also a biological inhibitor of centrosome duplication, as it inhibits Mps1 kinase activity in vitro and at centrosomes by blocking activating autophosphorylation .

Other names for CETN3 include CEN3, CDC31 yeast homolog, EF-hand superfamily member, and centrin EF-hand protein 3 . While CETN3 shares structural similarities with other centrin family members, particularly CETN2, they are not functionally interchangeable in cellular processes.

What applications are CETN3 antibodies commonly used for in research?

CETN3 antibodies are versatile tools for investigating centrosome biology and CETN3 function across various experimental contexts. The most common applications include:

• Western Blotting (WB): Used to detect and quantify CETN3 protein expression in cell or tissue lysates. Most commercial CETN3 antibodies are validated for WB and can detect the ~20 kDa CETN3 protein band in human, mouse, and rat samples .

• Immunohistochemistry (IHC): Applied to tissue sections to visualize the spatial distribution of CETN3 in tissues, particularly useful for studying centrosome abnormalities in pathological conditions .

• Immunocytochemistry (ICC) and Immunofluorescence (IF): Employed to examine the subcellular localization of CETN3, particularly its association with centrioles and centrosomes. These techniques are essential for studying the centrosomal functions of CETN3 .

• ELISA: Used for quantitative detection of CETN3 in samples, though less commonly employed than the imaging-based techniques .

For most research applications, antibodies that recognize the human, mouse, and rat CETN3 proteins are available, making them suitable for comparative studies across species .

How should I select the appropriate CETN3 antibody for my specific experiment?

Selecting the optimal CETN3 antibody requires careful consideration of several experimental factors:

• Antibody Type: Choose between polyclonal antibodies, which recognize multiple epitopes and provide high sensitivity, or monoclonal antibodies, which offer high specificity for a single epitope. For detailed localization studies of CETN3 at centrosomes, monoclonal antibodies may provide better specificity .

• Species Reactivity: Verify that the antibody recognizes CETN3 in your experimental species. Most commercial antibodies react with human, mouse, and rat CETN3, but cross-reactivity with other species should be confirmed before use .

• Application Compatibility: Ensure the antibody is validated for your specific application. Some antibodies work well for Western blotting but may perform poorly in immunofluorescence or vice versa .

• Epitope Location: Consider which region of CETN3 the antibody recognizes. For studying protein-protein interactions, such as CETN3-Mps1 binding, antibodies targeting regions away from interaction domains are preferable to avoid interference .

• Validation Data: Review published literature or supplier data that demonstrates antibody specificity. Ideally, the antibody should show absence of signal in CETN3 knockout samples, as demonstrated in studies using Cetn3 GT/GT mice .

For dual-labeling experiments examining CETN3 and CETN2 interactions, selecting antibodies raised in different host species will facilitate simultaneous detection without cross-reactivity issues.

What controls should I include when working with CETN3 antibodies?

Implementing appropriate controls is essential for reliable interpretation of results with CETN3 antibodies:

• Positive Controls: Include samples known to express CETN3, such as A549, NCI-H1299, or HCT 116 cell lines, which have been documented to express detectable levels of CETN3 protein .

• Negative Controls:

  • Primary antibody omission control to assess background staining

  • Ideally, CETN3 knockout or knockdown samples if available, similar to the Cetn3 GT/GT mice described in the literature

  • Isotype control antibody to evaluate non-specific binding

• Peptide Competition Control: Pre-incubating the CETN3 antibody with its immunizing peptide should abolish specific staining, confirming antibody specificity.

• Loading Controls: For Western blot analysis, include appropriate loading controls such as GAPDH, β-actin, or α-tubulin to normalize CETN3 expression levels.

• Cross-Reactivity Assessment: When studying both CETN2 and CETN3, verify that the antibodies do not cross-react between these related proteins. This is particularly important given their structural similarities but distinct functions .

For cellular localization studies, co-staining with established centrosomal markers (e.g., γ-tubulin) provides additional validation of centrosomal CETN3 localization.

How should I optimize Western blotting protocols for CETN3 detection?

Optimizing Western blotting protocols for CETN3 detection requires attention to several technical considerations:

• Gel Percentage: Use higher percentage gels (12-15% SDS-PAGE) to achieve good resolution of the relatively small CETN3 protein (19.6 kDa) . This allows better separation from other similarly sized proteins.

• Sample Preparation:

  • Use lysis buffers containing calcium chelators (EGTA/EDTA) with caution, as they may affect CETN3's calcium-binding properties

  • Include protease inhibitors to prevent degradation

  • For phosphorylation studies, add phosphatase inhibitors to preserve phosphorylation states

• Antibody Dilution: Start with the manufacturer's recommended dilution (typically 1:1000 for CETN3 antibodies) and optimize as needed . For weaker signals, consider longer incubation times rather than higher antibody concentrations to maintain specificity.

• Blocking Conditions: 5% non-fat dry milk in TBST is generally effective, but for phospho-specific detection, BSA-based blocking buffers are preferable.

• Visualization Method: For low abundance detection, consider using enhanced chemiluminescence (ECL) or fluorescent secondary antibodies with appropriate imaging systems.

• Loading Amount: Load sufficient protein (typically 20-30 μg of whole cell lysate) to detect CETN3, as demonstrated in published protocols using A549, NCI-H1299, and HCT 116 cell lines .

For comparing CETN3 levels across different experimental conditions, use quantitative Western blotting with appropriate normalization to loading controls and biological replicates for statistical analysis.

How can I analyze the interaction between CETN3 and Mps1 kinase in centrosome duplication?

Investigating the CETN3-Mps1 interaction requires sophisticated approaches that can detect both physical interactions and functional consequences:

• Co-immunoprecipitation (Co-IP):

  • Immunoprecipitate Mps1 and blot for CETN3, or vice versa

  • Use crosslinking agents like DSP (dithiobis[succinimidyl propionate]) to stabilize transient interactions

  • Include both calcium-containing and calcium-free conditions, as calcium binding might affect interaction dynamics

• In vitro kinase assays:

  • Purify recombinant CETN3 and Mps1 proteins

  • Establish dose-response experiments with varying CETN3:Mps1 ratios to assess inhibitory effects

  • Monitor Mps1 autophosphorylation at Thr-676 (a known site of T-loop autoactivation) in the presence and absence of CETN3

  • Analyze Mps1-dependent phosphorylation of CETN2 with varying concentrations of CETN3 to demonstrate the inhibitory effect

• Proximity ligation assay (PLA):

  • Use PLA to visualize CETN3-Mps1 interactions in situ at the centrosome

  • Combine with cell cycle markers to assess temporal dynamics of the interaction

• Centrosome duplication assays:

  • Employ S-phase arrest with hydroxyurea or aphidicolin to induce centrosome reduplication

  • Compare centrosome numbers in cells overexpressing CETN3 versus control cells

  • Use siRNA-mediated depletion of CETN3 to assess effects on centrosome number and Mps1 activity

• Structure-function analysis:

  • Generate CETN3 mutants with altered ability to bind Mps1

  • Assess their effects on Mps1 kinase activity and centrosome duplication

Research has demonstrated that CETN3 inhibits Mps1 kinase activity by blocking activating autophosphorylation and can prevent Mps1 from phosphorylating CETN2 even when Mps1 is present at 10-fold molar excess . This regulatory mechanism provides an important experimental system for studying centrosome duplication control.

What experimental approaches can distinguish the functions of CETN3 from other centrin family members?

Differentiating the specific functions of CETN3 from other centrins, particularly CETN2, requires targeted experimental strategies:

• Gene-specific knockdown or knockout models:

  • Use siRNA or shRNA for transient or stable knockdown of specific centrins

  • Generate CRISPR/Cas9-mediated knockout cell lines for individual centrins

  • Utilize conditional knockout mouse models such as the gene-trapped Cetn3 mice (Cetn3 GT/GT) described in the literature

  • Create double knockout models (e.g., Cetn2−/−;Cetn3 GT/GT) to assess functional redundancy and synergistic effects

• Rescue experiments:

  • Deplete endogenous CETN3 and express siRNA-resistant wildtype or mutant CETN3

  • Perform cross-complementation studies by expressing CETN2 in CETN3-depleted cells and vice versa

  • Use chimeric proteins containing domains from different centrins to map functional regions

• Localization studies:

  • Perform detailed co-localization analyses of different centrins throughout the cell cycle

  • Use super-resolution microscopy (STED, STORM, or SIM) to resolve the precise arrangement of different centrins within centrosomal structures

• Binding partner analysis:

  • Conduct comparative immunoprecipitation followed by mass spectrometry to identify unique and shared binding partners

  • Focus on interactions specific to CETN3, such as its inhibitory binding to Mps1

• Functional readouts:

  • Compare effects on centrosome duplication, as CETN3 inhibits while CETN2 promotes this process

  • Assess centriole incorporation, as CETN3 prevents incorporation of CETN2 into centrioles

  • Measure ERG responses in photoreceptors of mouse models with varying centrin genotypes (e.g., Cetn2−/−;Cetn3 GT/GT vs. Cetn3 GT/GT)

Published studies have demonstrated that despite structural similarities, CETN2 and CETN3 are not functionally interchangeable. CETN3 acts as a biochemical inhibitor of Mps1 catalytic activity and a biological inhibitor of centrosome duplication, whereas CETN2 phosphorylation by Mps1 promotes centriole assembly .

How do I design experiments to study CETN3's role in the TREX-2 complex and mRNA export?

Investigating CETN3's function in the TREX-2 complex requires specialized approaches focused on nuclear pore function and mRNA export processes:

• Subcellular fractionation and biochemical analysis:

  • Isolate nuclear envelope fractions to enrich for nuclear pore complexes

  • Perform immunoprecipitation of TREX-2 components followed by Western blotting for CETN3

  • Use density gradient centrifugation to separate TREX-2 complex from other nuclear structures

• High-resolution imaging of nuclear pores:

  • Implement super-resolution microscopy to visualize CETN3 localization relative to other TREX-2 components

  • Use correlative light and electron microscopy (CLEM) to precisely map CETN3's position within nuclear pore architecture

  • Perform live-cell imaging with fluorescently tagged CETN3 to track dynamics at nuclear pores

• mRNA export assays:

  • Employ fluorescence in situ hybridization (FISH) with oligo(dT) probes to visualize poly(A)+ RNA distribution after CETN3 depletion

  • Use MS2-GFP reporter systems to track specific mRNA export in real-time

  • Analyze nuclear/cytoplasmic ratios of various mRNAs by fractionation followed by RT-qPCR after CETN3 manipulation

• Protein-protein interaction mapping:

  • Identify CETN3 binding sites on other TREX-2 components using peptide arrays or hydrogen-deuterium exchange mass spectrometry

  • Generate CETN3 mutants with altered ability to incorporate into the TREX-2 complex

  • Perform proximity-dependent biotin identification (BioID) with CETN3 as bait to identify neighboring proteins at nuclear pores

• Functional TREX-2 assays:

  • Measure transcription-coupled mRNA export efficiency using reporter genes

  • Assess gene expression changes genome-wide after CETN3 depletion using RNA-seq

  • Evaluate effects of calcium concentration changes on CETN3-mediated TREX-2 functions

For these studies, it's important to distinguish CETN3's role in mRNA export from its centrosomal functions by using appropriate controls and localization-specific CETN3 mutants that preferentially target either centrosomes or nuclear pores.

What are the best methods to study CETN3 phosphorylation and its functional significance?

Investigating CETN3 phosphorylation requires specialized techniques to detect, characterize, and functionally assess phosphorylation events:

• Phosphorylation site identification:

  • Perform mass spectrometry analysis of immunoprecipitated CETN3 to identify phosphorylation sites

  • Use phospho-specific antibodies if available, or develop new ones for confirmed sites

  • Employ Phos-tag SDS-PAGE to separate phosphorylated from non-phosphorylated CETN3 species

• Kinase identification:

  • Conduct in vitro kinase assays with purified candidate kinases and recombinant CETN3

  • Perform kinase inhibitor screens to identify relevant kinases in cellular contexts

  • Use phospho-proteomic approaches after kinase knockdown/overexpression to determine effects on CETN3 phosphorylation

• Functional analysis of phosphorylation sites:

  • Generate phospho-mimetic (S/T→D/E) and phospho-deficient (S/T→A) CETN3 mutants

  • Express these mutants in CETN3-depleted cells and assess functional rescue

  • Compare effects on centrosome duplication, TREX-2 complex formation, and Mps1 inhibition

• Cell cycle-dependent phosphorylation:

  • Synchronize cells at different cell cycle stages and analyze CETN3 phosphorylation patterns

  • Use live-cell imaging with phospho-sensors to track CETN3 phosphorylation dynamics in real-time

  • Correlate phosphorylation status with centrosome duplication events

• Regulation of Mps1 interaction:

  • Determine how CETN3 phosphorylation affects its ability to inhibit Mps1 kinase activity

  • Assess whether Mps1 can phosphorylate CETN3 in a feedback regulatory mechanism

  • Investigate if phosphorylation affects CETN3's ability to prevent CETN2 incorporation into centrioles

While less is known about CETN3 phosphorylation compared to CETN2 phosphorylation, understanding these regulatory mechanisms would provide important insights into the differential functions of centrin family members and their roles in centrosome duplication control.

How can I characterize CETN3 function in photoreceptor cells specifically?

Investigating CETN3's role in photoreceptor cells requires specialized techniques that address the unique cellular architecture and function of these specialized neurons:

• Genetic models for in vivo analysis:

  • Utilize available CETN3 knockout models such as Cetn3 GT/GT mice

  • Generate photoreceptor-specific conditional CETN3 knockout using Cre-lox systems under photoreceptor-specific promoters

  • Create compound mutants lacking multiple centrins (e.g., Cetn2−/−;Cetn3 GT/GT) to assess functional redundancy

• Functional assessment of photoreceptors:

  • Perform electroretinography (ERG) to measure scotopic a-wave and b-wave amplitudes in response to varying light intensities

  • Compare ERG responses between wild-type, Cetn3 GT/GT, and compound mutant mice

  • Use optomotor response tests to evaluate visual function behaviorally

• Structural analysis of photoreceptors:

  • Examine connecting cilium (CC) structure using transmission electron microscopy

  • Assess photoreceptor outer segment morphology and integrity

  • Implement immunofluorescence analysis to localize CETN3 within photoreceptor subcellular compartments

• Molecular interaction studies in photoreceptors:

  • Identify photoreceptor-specific CETN3 binding partners through co-immunoprecipitation followed by mass spectrometry

  • Investigate potential interactions with proteins implicated in ciliopathies or retinal degenerations

  • Examine CETN3's relationship to other connecting cilium components

• Ex vivo and in vitro approaches:

  • Establish retinal explant cultures from CETN3 mutant and control mice

  • Develop differentiated photoreceptors from stem cells with CETN3 modifications

  • Use AAV-mediated gene delivery to rescue or manipulate CETN3 expression in photoreceptors

Published research has shown that deletion of both CETN2 and CETN3 leads to significantly reduced scotopic ERG responses compared to deletion of CETN3 alone, suggesting a cooperative function in photoreceptor cells . The Cetn2−/−;Cetn3 GT/GT mice produced significantly smaller a-wave and b-wave amplitudes compared with Cetn2+/−;Cetn3 GT/GT littermates, indicating that centrins play important roles in photoreceptor function beyond structural roles in centrosomes .

What are common challenges when working with CETN3 antibodies and how can I overcome them?

Researchers frequently encounter several challenges when working with CETN3 antibodies, each requiring specific troubleshooting approaches:

• Cross-reactivity with other centrin family members:

  • Validate antibody specificity using samples from CETN3 knockout models

  • Perform peptide competition assays to confirm specificity

  • Consider using monoclonal antibodies that target unique epitopes of CETN3

  • Test antibodies against recombinant CETN2 and CETN3 proteins to assess cross-reactivity

• Low signal-to-noise ratio in immunofluorescence:

  • Optimize fixation methods (compare paraformaldehyde, methanol, or combined protocols)

  • Test different permeabilization agents (Triton X-100, saponin, digitonin)

  • Increase blocking time and concentration to reduce background

  • Employ tyramide signal amplification for detection of low-abundance CETN3

• Variability in centrosomal staining:

  • Use cell cycle synchronization to obtain uniform centrosomal signals

  • Co-stain with established centrosomal markers like γ-tubulin

  • Optimize antibody concentration and incubation conditions

  • Consider super-resolution microscopy techniques for better resolution of centrosomal structures

• Inconsistent Western blot results:

  • Use fresh lysates and avoid repeated freeze-thaw cycles

  • Optimize transfer conditions for small proteins (19.6 kDa)

  • Consider using gradient gels or higher percentage gels (15%) for better resolution

  • Test different membrane types (PVDF vs. nitrocellulose) for optimal protein binding

• Batch-to-batch variability in antibodies:

  • Purchase antibodies in larger quantities to minimize lot changes

  • Validate each new lot against previous lots using identical samples

  • Consider generating recombinant antibodies for consistent performance

  • Keep detailed records of antibody performance with specific lots

By systematically addressing these challenges, researchers can significantly improve the reliability and reproducibility of experiments involving CETN3 antibodies.

How should I design experiments to study CETN3 and CETN2 functional differences?

Designing experiments to distinguish between CETN3 and CETN2 functions requires careful consideration of their distinct yet related roles:

• Sequential and simultaneous knockdown/knockout studies:

  • Deplete CETN2 and CETN3 individually and in combination

  • Assess phenotypic differences in centrosome number, structure, and function

  • Compare effects on cell cycle progression and centriole assembly

  • Quantify differences in centrosome reduplication after hydroxyurea treatment

• Domain swap experiments:

  • Generate chimeric proteins exchanging domains between CETN2 and CETN3

  • Express these chimeras in cells depleted of endogenous centrins

  • Identify domains responsible for specific functions, such as Mps1 binding or centriole incorporation

• Comparative interaction studies:

  • Perform parallel immunoprecipitation experiments with CETN2 and CETN3

  • Identify common and unique binding partners through mass spectrometry

  • Focus on differential interactions with Mps1 kinase

  • Quantify binding affinities using biophysical methods (ITC, SPR, MST)

• Phosphorylation analysis:

  • Compare phosphorylation patterns of CETN2 and CETN3 throughout the cell cycle

  • Investigate how CETN3 prevents Mps1-mediated phosphorylation of CETN2

  • Generate phospho-mimetic and phospho-deficient mutants of both proteins

• Localization dynamics:

  • Track GFP-tagged CETN2 and CETN3 throughout the cell cycle using live-cell imaging

  • Analyze how CETN3 prevents incorporation of CETN2 into centrioles

  • Compare recovery kinetics using fluorescence recovery after photobleaching (FRAP)

Research has demonstrated that CETN3 is both a biochemical inhibitor of Mps1 catalytic activity and a biological inhibitor of centrosome duplication, whereas CETN2 phosphorylation by Mps1 promotes centriole assembly . These functional differences provide a foundation for comparative experimental designs.

How can CETN3 antibodies be utilized in cancer research?

CETN3 antibodies offer several valuable applications in cancer research, particularly in studying centrosome abnormalities that are hallmarks of many cancers:

• Centrosome amplification assessment:

  • Use CETN3 antibodies to quantify centrosome numbers in tumor samples

  • Compare centrosome profiles between normal and malignant tissues

  • Correlate centrosome abnormalities with clinical outcomes and cancer aggressiveness

• Cancer cell line characterization:

  • Analyze CETN3 expression levels across cancer cell line panels (e.g., NCI-60, CCLE)

  • Investigate how CETN3 expression correlates with sensitivity to mitotic inhibitors

  • Assess centrosome structure in cell lines with varying degrees of chromosomal instability

• Diagnostic and prognostic applications:

  • Develop immunohistochemical protocols using CETN3 antibodies for pathology applications

  • Evaluate CETN3 as part of multiplex immunofluorescence panels for cancer classification

  • Investigate associations between CETN3 expression/localization and treatment response

• Therapeutic target identification:

  • Screen for compounds that modulate CETN3-Mps1 interactions

  • Assess effects of CETN3 manipulation on cancer cell sensitivity to centrosome-targeting drugs

  • Investigate synthetic lethal interactions with CETN3 depletion in different cancer backgrounds

• Cancer-specific CETN3 alterations:

  • Analyze cancer genome databases for CETN3 mutations or expression changes

  • Investigate functional consequences of cancer-associated CETN3 variants

  • Develop antibodies specific to cancer-associated CETN3 modifications

Human lung carcinoma (A549, NCI-H1299) and colorectal carcinoma (HCT 116) cell lines have been used successfully for CETN3 antibody validation and could serve as model systems for cancer-focused CETN3 research .

What new technologies could enhance CETN3 research in the future?

Emerging technologies offer exciting opportunities to advance CETN3 research beyond current limitations:

• Advanced imaging techniques:

  • Implement live-cell super-resolution microscopy to track CETN3 dynamics at centrosomes

  • Use expansion microscopy to resolve molecular organization within centriolar structures

  • Apply cryo-electron tomography to visualize CETN3 in its native cellular environment

  • Develop CETN3-specific fluorescent biosensors to monitor calcium binding or phosphorylation states

• Genome editing advances:

  • Create endogenously tagged CETN3 cell lines using CRISPR/Cas9 knock-in strategies

  • Generate conditional degron systems for rapid and reversible CETN3 depletion

  • Develop base editing approaches to introduce specific CETN3 mutations without double-strand breaks

• Proteomics and interactomics:

  • Apply proximity labeling techniques (BioID, TurboID, APEX) centered on CETN3

  • Implement crosslinking mass spectrometry to map CETN3 interaction surfaces

  • Use quantitative interaction proteomics to assess how CETN3 complexes change throughout the cell cycle

• Structural biology approaches:

  • Determine high-resolution structures of CETN3 in complex with binding partners like Mps1

  • Implement AlphaFold2 or RoseTTAFold to predict CETN3 interactions computationally

  • Use single-particle cryo-EM to visualize larger CETN3-containing complexes

• Single-cell technologies:

  • Apply single-cell proteomics to measure CETN3 levels across cell populations

  • Implement spatial transcriptomics to map CETN3 mRNA localization in tissues

  • Develop single-molecule tracking to follow individual CETN3 molecules in living cells

These technological advances will enable researchers to address fundamental questions about CETN3 function with unprecedented precision and resolution, potentially revealing new aspects of centrosome biology and mRNA export mechanisms.

How might research on CETN3 contribute to understanding ciliopathies and retinal disorders?

CETN3 research has significant implications for understanding ciliopathies and retinal disorders based on its roles in centriole/basal body biology:

• Photoreceptor connecting cilium (CC) formation and maintenance:

  • Investigate CETN3's role in CC assembly and integrity in photoreceptors

  • Compare CC ultrastructure in wild-type versus Cetn3 GT/GT mouse retinas

  • Assess whether CETN3 mutations could contribute to photoreceptor degeneration

• Functional consequences in retinal physiology:

  • Analyze electrophysiological changes in photoreceptors lacking CETN3

  • Compare scotopic ERG responses between control and CETN3-deficient models

  • Investigate mechanisms underlying reduced ERG a-wave and b-wave amplitudes in Cetn2−/−;Cetn3 GT/GT mice

• Genetic screening in patient populations:

  • Screen CETN3 for mutations in patients with unexplained retinopathies

  • Analyze potential correlations between CETN3 variants and disease severity

  • Develop genetic models of identified patient mutations

• Therapeutic development opportunities:

  • Evaluate gene therapy approaches to correct CETN3 deficiencies in photoreceptors

  • Assess pharmacological modulation of CETN3-dependent pathways for therapeutic potential

  • Explore stem cell-based approaches for retinal repair using CETN3 as a marker

• Broader ciliopathy connections:

  • Investigate CETN3's role in primary cilia formation in non-retinal tissues

  • Assess potential contributions to other ciliopathy manifestations (renal, hepatic, neurological)

  • Compare CETN3 function across different ciliated cell types

Research has shown that while deletion of CETN3 alone (Cetn3 GT/GT) does not cause syndromic ciliopathy, combined deletion with CETN2 (Cetn2−/−;Cetn3 GT/GT) leads to significant photoreceptor dysfunction as measured by ERG . This suggests that CETN3 may contribute to retinal health through redundant mechanisms with other centrin family members.